Position of the Transparency Council – Trandate (labetalol)
At its meeting on 25 November 2024, the Transparency Council adopted position No. 134/2024 on the appropriateness of authorising the reimbursement of the drug Trandate (labetalol), for the indication of hypertension in pregnant women
Publication of the position >>